Sjogren's Syndrome Clinical Trial
Official title:
Clinical and Laboratory Evaluation of the Autonomic Nervous System in Primary Sjogren's Syndrome
Verified date | April 10, 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
Sj(SqrRoot)(Delta)gren s Syndrome (SS) is an autoimmune disease that affects the glands that
produce saliva and tears, causing dry eyes and dry mouth.
Researchers do not know the exact cause of SS, but they believe that it may be caused by
abnormalities in the autonomic nervous system (ANS) that stimulate these glands.
Objectives:
To better understand ANS function in patients with SS.
To compare information about ANS function in healthy individuals and in patients with SS.
Eligibility:
Patients with Sj(SqrRoot)(Delta)gren s Syndrome who are 18 years of age and older, and who
are not pregnant or breastfeeding.
Participants will be asked to taper or discontinue the use of certain medications or dietary
supplements before the ANS testing.
Participants must be willing to discontinue the use of alcohol and tobacco 24 hours prior to
testing.
Design:
The study will require one inpatient admission and/or outpatient visits to the NIH Clinical
Center.
The following tests and procedures will be performed:
- Saliva, tear, and sweat production measurements to evaluate the function of glands.
- Testing of changes to the cardiovascular system, including blood pressure and blood flow
testing, and an electrocardiogram designed to evaluate hemodynamic changes controlled by
the ANS.
- Testing of changes to the gastrointestinal system, including a swallowing assessment
study, barium swallow study, and gastric emptying study designed to evaluate
gastrointestinal function controlled by the ANS.
- Tests to evaluate the ANS function in response to certain drugs (edrophonium, glucagon
and acetylcholine).
- Self-reported questionnaire on ANS function and emotional/psychological well-being.
Additional procedures and tests may include the following:
- Blood samples.
- Optional skin biopsy to study sweat glands and nerve supply of the skin.
Status | Completed |
Enrollment | 28 |
Est. completion date | April 10, 2014 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Diagnosis of primary Sjogren s syndrome based on American-European Consensus Group Sjogren s syndrome classification criteria or healthy volunteers. 2. Both genders and all minorities. 3. Age at entry at least 18 and less than 65 years. EXCLUSION CRITERIA: 1. Current use of medications known to significantly influence the activity of the sympathetic or parasympathetic nervous system if they cannot be held safely at the time of ANS testing 2. Known co-existing diagnosis of ANS dysfunction (for healthy volunteers) 3. Medications-requiring diabetes mellitus 4. Diabetic autonomic neuropathy 5. Vitamin B12, folate deficiency, requiring replacement 6. Hepatic failure (AST or ALT greater than 1.5 x upper limit of normal) 7. Renal failure (GFR less than 30 ml/min, as estimated by the MDRD) 8. Congestive heart failure (Class II-IV) 9. Refractory ventricular arrhythmias 10. Symptomatic coronary heart disease 11. Previously established diagnosis of sinus node dysfunction 12. Severe anemia (Hgb less than 8) 13. Psychosis 14. Pregnant or lactating women 15. A candidate subject is excluded if, in the judgment of the Principal Investigator, protocol participation would place the subject at substantially increased acute medical risk. 16. Not able to provide informed consent Medications: A candidate subject is excluded if clinical considerations require that the subject continue treatment with a drug likely to interfere with the scientific results i.e. a tricyclic antidepressant or fludrocortisone. Subjects with known or suspected allergy or hypersensitivity to any test drug are excluded from receiving that drug. Subjects who must take medications daily in the following categories are excluded: tricyclic antidepressants, beta blockers, barbiturates, if they cannot be safely held during testing. Subjects unable to discontinue nicotine or alcohol temporarily are excluded. Subjects are not to discontinue any medications before the subject or the subject s physician discusses this with the Principal Investigator, Dr. Nikolov, or the Associate Investigator, Dr. Goldstein. If it is decided that discontinuing medications would be unsafe, then the subject is excluded from the study. Subjects must discontinue use of alcohol and tobacco throughout the period of testing in the protocol. Herbal Medicines and Dietary Supplements: Certain herbal medicines or dietary supplements are known or suspected to interfere with the experimental results, and such herbal medicines or dietary supplements must be discontinued before enrollment in the study. For many herbal medicines or dietary supplements, the mechanisms of action and therefore the possible effects on the experimental results are unknown. In cases where the subjects wish to continue their herbal medicines or dietary supplements while on study, and search of the available medical literature fails to identify effects that are known or expected to interfere with the experimental results, then the subjects may participate. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 Oct 16;349(16):1526-33. — View Citation
Björklund H, Dalsgaard CJ, Jonsson CE, Hermansson A. Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. Cell Tissue Res. 1986;243(1):51-7. — View Citation
Sharma RV, Mathur SN, Ganguly J. Studies on the relative biopotencies and intestinal absorption of different apo-beta-carotenoids in rats and chickens. Biochem J. 1976 Aug 15;158(2):377-83. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT04968912 -
A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT00809003 -
Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease
|
N/A | |
Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
Completed |
NCT05005806 -
Fish Oil (Omega 3 ) in Sjogren's Syndrome
|
Phase 2/Phase 3 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Terminated |
NCT04143841 -
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Recruiting |
NCT06104124 -
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
|
Phase 3 | |
Recruiting |
NCT05115487 -
Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
|
||
Recruiting |
NCT06437652 -
An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome
|
||
Recruiting |
NCT05383677 -
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT03938207 -
Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
|
||
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Completed |
NCT04546542 -
Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
|
||
Recruiting |
NCT05085431 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
|
Early Phase 1 | |
Completed |
NCT01369589 -
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
|
Phase 1/Phase 2 | |
Completed |
NCT00001953 -
The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers
|
N/A | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 |